8month17On the morning of the same day, the National Health Commission held a press conference regarding the 'Guiding Opinions on Further Improving and Implementing Active Fertility Support Measures' (hereinafter referred to as the 'Opinions').8month16Compiled by the National Health Commission, National Development and Reform Commission, etc.17The department has issued a notice to promote the in-depth implementation of the policy allowing a couple to have three children.
The 'Opinions' mention the gradual inclusion of assisted reproductive projects into medical insurance coverage. What aspects will this actually have an impact on the assisted reproductive industry? What are the main pain points for domestic assisted reproductive enterprises at present, and which companies are deploying in the assisted reproductive business sector? Frost & SullivanFrost & Sullivan,Li Qian, Consulting Director for Healthcare in Greater China at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), was interviewed by the Economic Observer. Jointly explore the impacts that the 'Opinions' will have on the assisted reproductive service market.
Economic Observer
8month17On the morning of the same day, the National Health Commission held a press conference regarding the 'Guiding Opinions on Further Improving and Implementing Active Fertility Support Measures' (hereinafter referred to as the 'Opinions').8month16Compiled by the National Health Commission, National Development and Reform Commission, etc.17The department has issued a notice to promote the in-depth implementation of the policy allowing a couple to have three children.
The Opinions aim to improve the maternity leave and benefits guarantee mechanism, strengthen supportive measures such as housing and taxation, and build a friendly employment environment for families with children.7In one aspect, it proposes to improve and implement proactive fertility support measures in finance, taxation, insurance, education, housing, employment, etc.20Specific measures.
The 'Opinions' clearly propose to strengthen reproductive health services. Expand the pilot program for labor analgesia, standardize related diagnosis and treatment practices, and improve the level of labor analgesia. Guide and promote medical institutions to provide targeted services to the public through means such as health education, psychological counseling, traditional Chinese medicine services, drug therapy, surgical treatment, and assisted reproductive technology, in order to improve the prevention and treatment level of infertility. Promote the construction of the assisted reproductive technology system, improve the quality control network, and strengthen service monitoring and information management.
Regarding the improvement of social insurance systems related to maternity insurance, the 'Opinions' state that localities will be guided to comprehensively consider factors such as the affordability of medical insurance (including maternity insurance) funds and relevant technical standardization, and gradually include appropriate childbirth analgesia and assisted reproductive technology programs within the fund payment scope according to procedures.
Li Qian, Senior Consulting Director of Frost & Sullivan's Healthcare Industry, told ECONOMIC OBSERVATIONS that the measures in the 'Opinions' to gradually include assisted reproductive programs within medical insurance coverage further improve the medical security level for infertile patients, effectively reducing their economic burden and increasing the accessibility of assisted reproductive services. This will boost the rapid rise in the penetration rate of assisted reproductive services in China, promote the healthy development of the assisted reproductive industry, and the market is expected to enter a period of rapid development.
Affected by this news, todayAThird-child shares and concept stocks related to assisted reproduction are active. As of close, Weichuang Technology Co., Ltd. and Hanshang Group Co., Ltd. hit the daily limit up, while Adopt Technology Co., Ltd. rose more than7%Changhong Technology rose more than6%Tai'an Hall, Sichuang Co., Ltd., Changchun High-tech Group Co., Ltd., etc. rose more than3%.
windData shows that currentlyAAmong the listed companies, there are a total of22Home, our business covers infertility treatment, assisted reproductive genetic technology, assisted reproductive medical services, progesterone drugs, etc.
"
Li Qian stated that due to factors such as technical limitations, the production of upstream testing reagents, drugs, and medical devices in China's entire assisted reproductive industry is still mainly carried out by foreign companies. Domestic enterprises have not yet occupied a significant proportion of the market share. Currently, companies such as Desheng Biotech, BGI Genomics, KingMed, and AnnoUda are accelerating their layout in related fields.
According to her introduction, the market supervision of assisted reproductive services in China is strict. Due to factors such as scarce licenses, high approval difficulty, and uneven distribution of medical resources, the downstream of China's assisted reproductive industry is basically controlled by state-owned hospitals and multinational pharmaceutical companies. The entry threshold for the industry is high, with related enterprises including Jin Xin Reproductive Medicine.
Galaxy Securities also pointed out that the penetration rate of China's assisted reproductive market is relatively low, leaving ample room for improvement.2018In China, there were approximately56.8Only a fraction of the total number of patients (10,000) received assisted reproductive services in that year4780One in ten infertile couples1.2%In the future, with deeper understanding of assisted reproductive technology, increased per capita disposable income, and the relaxation of policies encouraging childbirth, the penetration rate of assisted reproduction in China is expected to continue to rise.
Before this article was published, many regions had already attempted to promote the inclusion of assisted reproduction in medical insurance reimbursement. This year2In January, Beijing planned to16Assisted reproductive technology has been included in Class A medical insurance reimbursement, but it was later announced that implementation will be postponed. Provinces such as Zhejiang have also stated that they will actively promote the inclusion of assisted reproduction in medical insurance, although this has not yet been implemented.
"
According to Li Qian's analysis, the prices of assisted reproductive services are expensive, and at the same time, there is a high demand for these services. Therefore, including assisted reproductive programs in medical insurance may lead to a surge in medical insurance fund expenditures, which could pose challenges to local medical insurance funds.Continuing challenges affect the stable operation of medical insurance funds, necessitating careful consideration in combination with the local medical insurance fund's operational conditions regarding the types of assisted reproductive technology projects to be included in medical insurance, as well as their payment scope and level.
Ping An Securities stated in their latest research report that higher prices have deterred some middle- and low-income individuals from participating in assisted reproductive programs, resulting in a slower rate of penetration. The state attaches importance to the decline in fertility rates, and some assisted reproductive programs are expected to be accelerated into medical insurance coverage. With future inclusion of assisted reproductive programs in medical insurance, it will improve patient accessibility and is expected to drive a rapid release of demand on the supply side, thereby promoting industry development.
*This article is reprinted from Economic Observer. Reporter Yu Shiqi , Original title: 17The department has issued documents to improve and implement proactive measures for supporting fertility, including the inclusion of assisted reproduction in medical insurance. 'Further progress' is expected. ">
